Skip to content

Aducanumab is an investigational drug and is not approved for use in the U.S. or any other country.


Press Releases

November 4, 2019

Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019

October 22, 2019

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

Learn more about Alzheimer’s disease

click here


Michel Vounatsos, Chief Executive Officer

Alfred W. Sandrock, Jr., M.D., Ph.D., Executive Vice President, Research & Development and Chief Medical Officer

Samantha Budd Haeberlein, Vice President, Late-Stage Clinical Development